TABLE 5.
Appropriateness of antifungal therapies
| Item | No. (%) of evaluated therapy episodes or length of treatment in indicated period |
P value | ||
|---|---|---|---|---|
| 1st (n = 105a) | 2nd (n = 109a) | 3rd (n = 204a) | ||
| Overall appropriateness (no. of episodes per 1st, 2nd, 3rd period) | 32 (30.5) | 29 (26.6) | 128 (62.7) | <0.001 |
| Indication | 100 (95.2) | 103 (94.5) | 190 (93.1) | 0.739 |
| Drug choice | 96 (91.4) | 99 (90.8) | 200 (98.0) | 0.022 |
| Dosage | 62 (59.0) | 81 (74.3) | 192 (94.1) | 0.001 |
| Microbiologic adjustment, if possible (n = 47, 50, 95) | 43 (91.5) | 43 (86.0) | 92 (96.8) | 0.054 |
| Administration route (n = 29, 35, 46) | 10 (34.5) | 18 (51.4) | 23 (50.0) | 0.324 |
| Length of therapy (n = 89, 97, 153) | 57 (64.0) | 56 (57.7) | 115 (75.2) | 0.013 |
| Switch to another antifungal drug | 25 (23.8) | 26 (23.9) | 27 (13.2) | 0.021 |
| Unresponsiveness to first-line antifungal treatment | 15 (14.3) | 8 (7.3) | 11 (5.4) | 0.033 |
| Antifungal-related adverse reaction | 6 (5.7) | 3 (2.8) | 7 (3.4) | 0.508 |
| 30-day mortality | 20 (19.0) | 17 (15.6) | 56 (27.5) | 0.050 |
| Duration of antifungal treatment periods [median no. of days (IQR)] | 13 (8.25–19.0) | 14 (9.0–20.0) | 14 (10.0–19.0) | 0.560 |
a
Or value for subgroup as indicated.